RedHill Biopharma Reshapes Talicia Franchise and Strengthens Balance Sheet in 2025 Results

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks RedHill Biopharma ( (RDHL) ) has shared an announcement. RedHill Biopharma on April 27, 2026 reported its full-year 2025 results, highlighting a transformative year marked by the creation of Talicia Holdings Inc. and a U.S. co-commercialization deal with Cumberland Pharmaceuticals, which took a 30% stake in the new vehicle for $4 million. The company broadened Talicia’s reach through added Humana Part D coverage, new Middle East licensing that generated about $1.9 million in discontinued-operations revenue, and preparations for a fast-track marketing application in the U.K. RedHill also sharpened its R&D focus, advancing RHB-204 for Crohn’s disease under positive FDA feedback, progressing opaganib in a Phase 2 prostate cancer combination trial and other oncology indications, and positioning RHB-102 (Bekinda) as a potential therapy for GLP-1/GIP-related gastrointestinal side effects. Corporate moves included licensing RHB-102 to Hyloris outside North America for up to $60 million in milestones plus royalties, securing a $10 million equity line with Alumni Capital, and winning more than $10.5 million in New York court rulings against Kukbo, contributing to a swing from a $4.7 million capital deficiency in 2024 to $4.3 million positive equity and $4.1 million cash at year-end 2025. Management framed 2025 as a year of “tenacity” in a challenging sector, citing the restructured Talicia business, strategic partnerships and licensing, and a leaner cost base as drivers of improved financial footing. These initiatives position RedHill for future growth by leveraging co-commercialization platforms, ex-U.S. licensing, and a focused pipeline in large markets such as GLP-1 therapies, while continued realization of legal awards and access to additional capital remain important for liquidity and execution. Spark’s Take on RDHL Stock According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral. Score is held down primarily by weak financial performance (ongoing losses, negative equity, and negative operating/free cash flow). Technicals provide a partial offset with improving short-term trend and momentum, but longer-term trend and MACD remain unsupportive. Valuation impact is neutral due to missing P/E and dividend yield. To see Spark’s full report on RDHL stock, click here. More about RedHill Biopharma RedHill Biopharma Ltd. is a specialty biopharmaceutical company headquartered in Tel Aviv and Raleigh, listed on Nasdaq under the ticker RDHL. The company focuses on gastrointestinal and inflammatory diseases and oncology, with key assets including Talicia for H. pylori infection, opaganib as an add-on oncology therapy, and RHB-102 (Bekinda) for gastrointestinal indications, including GLP-1/GIP-related side effects. RedHill targets both U.S. and international markets through direct commercialization, partnerships, and licensing deals. Its strategy combines co-commercialization ventures, such as the Talicia Holdings Inc. structure in the U.S., and regional licensing agreements in territories like the Middle East and ex-North America, while maintaining a leaner operational footprint and a focused late-stage R&D pipeline. Average Trading Volume: 38,588 Technical Sentiment Signal: Sell Current Market Cap: $5.22M Learn more about RDHL stock on TipRanks’ Stock Analysis page.